Life Sciences»Pharmaceuticals»Therapeutic Area»CNS/Neurology
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016
| Lowest Prices Guaranteed | Length | Publisher | Published Date | SKU |
|---|---|---|---|---|
| from $2,000 | 86 Pages | Global Markets Direct | July, 2016 | GMD15094401 |
| Lowest Prices Guaranteed | |
| Price | from $2,000 |
|---|---|
| Length | 86 Pages |
| Publisher | Global Markets Direct |
| Published Date | July, 2016 |
| SKU | GMD15094401 |
Table of Contents
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016 Table of Contents
Global Markets Direct
- Introduction
- Global Markets Direct Report Coverage
- Peripheral Neuropathy (Sensory Neuropathy) Overview
- Therapeutics Development
- Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview
- Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis
- Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies
- Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies
- Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes
- Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development
- Araim Pharmaceuticals, Inc.
- CSL Limited
- GeNeuro SA
- Mitsubishi Tanabe Pharma Corporation
- Neuren Pharmaceuticals Limited
- Pfizer Inc.
- Pharnext SAS
- Polyneuron Pharmaceuticals AG
- RegeneRx Biopharmaceuticals, Inc.
- Sanofi
- Shire Plc
- Teijin Pharma Limited
- Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (baclofen + naltrexone + sorbitol) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aminoquinol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cibinetide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EDE-1204 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fingolimod hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GL-2045 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GNbAC-1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- immune globulin (human) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- immune globulin (human) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- immune globulin (human) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NNZ-2591 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PN-1007 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RGN-352 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SAR-184841 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Synthetic Peptides for Peripheral Neuropathy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects
- Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products
- Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones
- Featured News & Press Releases
- Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
- Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent
- Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy
- Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen
- Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
- May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016
- Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Late Stage Development, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Development, H2 2016
- Products under Development by Companies, H2 2016
- Products under Investigation by Universities/Institutes, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by CSL Limited, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pharnext SAS, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Sanofi, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Shire Plc, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Assessment by Combination Products, H2 2016
- Number of Products by Stage and Target, H2 2016
- Number of Products by Stage and Mechanism of Action, H2 2016
- Number of Products by Stage and Route of Administration, H2 2016
- Number of Products by Stage and Molecule Type, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H2 2016
- Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H2 2016
- List of Figures
- Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016
- Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Assessment by Combination Products, H2 2016
- Number of Products by Targets, H2 2016
- Number of Products by Stage and Targets, H2 2016
- Number of Products by Mechanism of Actions, H2 2016
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
- Number of Products by Routes of Administration, H2 2016
- Number of Products by Stage and Routes of Administration, H2 2016
- Number of Products by Molecule Types, H2 2016
- Number of Products by Stage and Molecule Types, H2 2016
Description
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016 Description
Global Markets Direct
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
- The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy)
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Search inside this report
| Single User License | $2,000 | |
|---|---|---|
| Site License | $4,000 | |
| Global Site License | $6,000 |
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
